Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Supplementary Dataset 11b - SILAC data for HEK293T-Subtiligase-Y217K-TM Pervanadate treated vs untreated

ABSTRACT: This dataset contains SILAC data for HEK293T-Subtiligase-Y217K-TM cells, pervanadate treated vs untreated. In Q20180417-03 and Q20180417-05, light cells were pervanadate treated and heavy cells were the control. In Q20180417-07 and Q20180417-09, heavy cells were pervanadate treated and light cells were the control.

INSTRUMENT(S): QExactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: James A. Wells

PROVIDER: MSV000084994 | MassIVE | Fri Feb 21 10:16:00 GMT 2020

SECONDARY ACCESSION(S): PXD017685

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Supplementary Dataset 11a - SILAC data for HEK293T-Subtiligase-TM Pervanadate treated vs untreated

Project description:This dataset contains SILAC data for HEK293T-subtiligase-TM cells, pervanadate treated vs. untreated. In Q20180412-02 and Q20180412-04, light cells were pervanadate treated and heavy cells were the control. In Q20180412-06 and Q20180412-08, heavy cells were pervandate treated and light cells were the control.

2020-02-20 | MSV000084992 | MassIVE

Supplementary Dataset 11c - SILAC data for HEK293T-Subtiligase-Y217D-TM Pervanadate treated vs untreated

Project description:This dataset contains SILAC data for HEK293T-subtiligase-Y217D-TM cells, pervanadate treated vs. untreated. In Q20180422-04, light cells were pervanadate treated and heavy cells were the control. In Q20180422-08 and Q20180422-10, heavy cells were pervanadate treated and light cells were the control.

2020-02-21 | MSV000084995 | MassIVE

Supplementary Dataset 9 - N-terminal peptides identified in subtiligase-Y217K-TM N terminomics experiments

Project description:This dataset contains N-terminal peptides enriched using subtiligase-Y217K-TM N terminomics from the surface of HEK293T cells.

2020-02-20 | MSV000084990 | MassIVE

Proteomics of groundwater microbiomes collected from five wells in Alberta, Canada

Project description:Groundwater samples were collected from five wells in Alberta, Canada. The sampling location and time are indicated in the table below. 13 to 29 genomes were assembled from each metagenome. Proteomic analyses were performed to investigate which genomes and genes were expressed in each well. Sample ID Location Latitude (NAD 83) Longitude (NAD 83) Sampling date 19GWC19026 218 Cluny 50.85 -112.84 30/07/2019 19GWC19028 114 Ross Creek 49.99 -110.46 31/07/2019 19GWC19045 265 Metiskow 52.42 -110.61 18/09/2019 19GWE00050 991 Cynthia 56.22 -117.81 04/09/2019 19GWE00515 33 Fort McMurray 56.98 -111.85 17/09/2019

2024-05-21 | PXD044305 | Pride

Supplementary Dataset 10 - N-terminal peptides identified in subtiligase-Y217D-TM N terminomics

Project description:This dataset contains N-terminal peptides enriched using subtiligase-Y217K-TM N terminomics.

2020-02-20 | MSV000084991 | MassIVE

Phosphoproteomic Response To MEK Inhibition

Project description:SILAC Heavy and Light cells were treated for 24 hours with each MEKi vs. Control in duplicate (Heavy/Light as well as Light/Heavy). For phosphoproteomic analysis, cells were treated for either 30 minutes or 24 hours with each MEKi vs. Control.

2019-11-12 | PXD002621 | Pride

Quantitative SILAC phosphoproteomics and proteomics of HL60 cells treated with covalent CDK7 inhibitor SY351

Project description:Using the covalent inhibitor SY-351 and quantitative SILAC phosphoproteomics, we identified CDK7 kinase substrates in human cells. We performed a double-label SILAC phosphoproteomics experiment, in which we metabolically labeled HL60 cells with light labeled (Lys0, Arg0) or heavy labeled (Lys8, Arg8) amino acids, which were treated with vehicle (DMSO) or 50 nM SY-351, followed by phosphopeptide enrichment and mass spectrometry analysis. The experimental design included two biological replicates of SY-351 treated heavy cells compared with DMSO treated light cells, a label-flip biological replicate of SY-351 light cells compared with DMSO treated heavy cells, and a null condition for which both heavy and light were treated with DMSO. The label-flip and null conditions control for systematic errors in phosphopeptide Heavy:Light SILAC ratios that are independent of the SY-351 treatment effect. We used a linear statistical model to capture these systematic errors, which improved our statistical power to detect phosphorylation sites that changed in abundance with SY-351 treatment.

2020-06-10 | MSV000085575 | MassIVE

Lymph node stromal cells: Control siRNA treated vs. Eif4g3 siRNA treated

Project description:Gene expression in the top, light and heavy polysome fractions of Eif4g3 siRNA treated lymph node stromal cells (LNSCs) compared to control-sIRNA treated samples This study was performed to examine whether the expression of certain genes in LNSCs is regulated by the translation factor, eukaryotic translation initiation factor 4 gamma 3 (Eif4g3).

2011-09-01 | GSE29152 | GEO

Density Transfer Data for Lachancea waltii DNA Replication Profile

Project description:Array data detailing the progression of DNA replication in the yeast Lachancea waltii. L. waltii cells were pregrown in heavy isotope medium and synchronized at early S phase. They were then released into normal medium, wherein DNA replication proceeds. Replicated DNA molecules are thus of heavy-light (HL) composition as compared to unreplicated molecules, which are heavy-heavy (HH). 4 time points were taken and the percent of heavy-light DNA was determined at each time point. The heavy-heavy and heavy-light DNA molecules were separated by ultracentrifugation, differentially labeled, and hybridized to a genomic array for L. waltii. The array thus shows the progression of DNA replication.

2012-05-09 | E-GEOD-35155 | biostudies-arrayexpress

H3K9bhb identification of CD8+Tm cells

Project description:MS/MS spectra of a tryptic H3K9 peptide identified from BHB-treated CD8+ Tm cells or 13C-labled BHB-treated memory T cells

2019-11-14 | PXD016044 | Pride